Primary HIV infection during chronic treatment with imatinib: impact on infection dynamics-Reference-Cited by-同舟云学术

Primary HIV infection during chronic treatment with imatinib: impact on infection dynamics

Published:2024-07-11 Issue:10 Volume:38 Page:1601-1604
ISSN:0269-9370
Container-title:AIDS
language:en
Short-container-title:

Author:

Bozzi Giorgio¹,Centazzo Matteo²³,Scaglioni Susanna²³,Butta Giacomo Maria¹³,Saltini Paola¹⁴,Liparoti Arianna¹⁴,Trombetta Elena⁵,Prati Daniele⁶,Gori Andrea¹⁷,Bandera Alessandra¹⁴,Manganaro Lara¹³

Affiliation:

1. Infectious Diseases Unit, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico

2. Department of Pharmacological and Biomolecular Sciences, University of Milan

3. INGM, National Institute of Molecular Genetics, Romeo ed Enrica Invernizzi

4. Department of Pathophysiology and Transplantation, University of Milan

5. Flow Cytometry Facility, Clinical Pathology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico

6. Department of Transfusion Medicine and Hematology, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan

7. Department of Biomedical Sciences for Health, School of Public Health, University of Milan, Milan, Italy.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Reference18 articles.

1. Dasatinib protects humanized mice from acute HIV-1 infection;Salgado;Biochem Pharmacol,2020

2. Cytotoxic cell populations developed during treatment with tyrosine kinase inhibitors protect autologous CD4+ T cells from HIV-1 infection;Vigón;Biochem Pharmacol,2020

3. SAMHD1 is the dendritic- and myeloid-cell-specific HIV-1 restriction factor counteracted by Vpx;Laguette;Nature,2011

4. Vpx relieves inhibition of HIV-1 infection of macrophages mediated by the SAMHD1 protein;Hrecka;Nature,2011

5. IL-7 induces SAMHD1 phosphorylation in CD4+ T lymphocytes, improving early steps of HIV-1 life cycle;Coiras;Cell Rep,2016